Will Hospira's Lack of a Dividend Hold It Back in 2014?

Hospira (NYSE: HSP) currently pays no dividend. Could this mean that shares struggle to keep pace with the S&P 500 this year?

Feb 21, 2014 at 7:22PM

As all Foolish investors know, dividends are often a key part of an investment portfolio. Indeed, numerous pieces of research over the years have shown that dividends, when reinvested, tend to make up a significant proportion, if not the majority, of total returns over the long run.

Therefore, companies that don't pay dividends may find themselves being left out in the cold by investors -- unless they can provide significantly higher rates of earnings growth to make up for it, that is.

Strong share price performance
One company that falls into this category is Hospira (NYSE:HSP). It didn't pay a dividend last year, but was able to grow earnings per share, or EPS, by a whopping 674%, although this growth rate is slightly misleading as it followed two highly challenging years for the company. The first, 2011, was a loss-making year, while 2012 saw only a modest profit. Nevertheless, shares have easily beaten the S&P 500 during the last year, with Hospira delivering gains of 41%, while the S&P has lagged behind with 22% gains.

A lack of dividends
Despite this marked improvement in profitability, Hospira is not forecast to pay a dividend in 2014 or 2015. This is in spite of the company being expected to deliver EPS growth of 2% and 7%, respectively, in those two years.

This situation may appear to be slightly frustrating for shareholders. Once the exceptional growth rates have shaken out and the company reverts to market average growth rates, which are forecast for 2014 and 2015, what could help drive the share price higher?

Potential catalysts
One potential catalyst could be the continued strengthening of the business, which the stock market has clearly warmed to during the last year, as shares have performed strongly. This strengthening is taking the form of, among other areas, increasing capacity at manufacturing facilities and modernizing Hospira's various plants, as well as seeking expansion in emerging markets.

Indeed, a recent presentation given by CEO Mike Ball included slides that showed the company was making progress in a number of key areas, such as those mentioned above. Furthermore, such improvements are delivering some benefits now, but seem likely to generate the majority of benefits in future years. So, with developments thus far improving sentiment, and pushing shares higher, it's possible that further steps forward with regards to strategy implementation could act as a catalyst for the share price.

Big changes at other pharmaceutical stocks
Of course, Hospira isn't the only Pharmaceutical major that's going through a period of change. Sector peer Bristol-Myers Squibb (NYSE:BMY) is attempting to transition from being a producer of mass-market drugs to a specialist, niche player. As with Hospira, the market seems to be warming to this strategic turnaround, with shares easily outperforming the index during the last year -- up 48% versus up 22% for the S&P 500.

The changes at Bristol-Myers Squibb have included a sale of its share of the joint venture with AstraZeneca (NYSE:AZN) for around $2.7 billion. This seems to make sense for both companies, and sees AstraZeneca continue its fight back against a patent cliff that was among the most challenging in the global Pharmaceutical industry. Although AstraZeneca's earnings are expected to fall in 2014 and 2015, they are expected to show growth after that, and shares have responded accordingly -- they were up 49% during the last year versus +22% for the S&P 500.

Looking ahead
Indeed, the strength shown during the last year in Hospira's share price seems to be in anticipation of the benefits from the changes that are being made by its management team. Although a dividend would doubtless be welcomed by shareholders, there seems to be adequate potential from the strategic changes being made to drive shares upwards during 2014 and, crucially, for them to continue to outperform the S&P 500 during the remainder of the year. 

Secure your future with nine rock-solid dividend stocks
One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks, as a group, handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it's true. However, knowing this is only half the battle. The other half is identifying which dividend stocks, in particular, are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

Peter Stephens owns shares of AstraZeneca. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers